



DIRECT GLOBAL MEDIA



BURZYNSKI RESEARCH INSTITUTE, INC– OTC: TICKER – BZYR

RESEARCH REPORT

Primum Non Nocere – First, Do no harm



BURZYNSKI RESEARCH INSTITUTE, INC.

BRIEF DESCRIPTION: Traded under the ticker symbol: BZYR (OTC)

Burzynski Research Institute (PINK: BZYR)-

Burzynski Research Institute (BRI) is based in Houston and Stafford, Texas, U.S.A., and is engaged in research and development of targeted gene therapies (antineoplastons or ANP) for the treatment of cancer. BRI was incorporated

under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name antineoplastons.

BRI believes ANP are useful in the treatment of human cancer, and is currently conducting Phase II clinical trials of ANP relating to the treatment of cancer and starting Phase III trials. ANP have not been approved for sale or use by the Food and Drug Administration of the United States Department of Health and Human Services ("FDA") or anywhere in the world.

In the event ANP receives such approval and are registered in the United States, Canada, or Mexico, of which there can be no assurance, BRI will commence commercial operations, which shall include the production, marketing, promotion and sale of ANP in the United States, Canada, or Mexico. In 2004, the FDA approved the designation of ANP as an "orphan drug" under the Orphan Drug Act of 1983, for the treatment of brainstem glioma. In 2008, ANP orphan drug designation by the FDA was extended to all gliomas. It is estimated that in 2010 more than 21,000 men and women in the U.S., will be diagnosed with glioma, with prevalence estimated at approximately 84,000 cases.

**THE CANCER INDUSTRY IS
QUITE LARGE WHICH
GENERATES IN EXCESS OF
APPROXIMATELY \$200 BILLION
PER YEAR WORLDWIDE.**

Orphan Drug Designation is granted by the FDA's Office of Orphan Drug Products Development, and is designed to encourage clinical development of products for use in rare diseases, or conditions usually defined as affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides an economic incentive that stimulates the development of new products in the oncology field, and allows for seven years of market exclusivity upon final FDA approval, as well as clinical study and R&D support, reduction in regulatory fees, and potential tax credit.

The system is the technology that allows for the rapid development of non-invasive, naturally derived topical solutions that have the ability to revitalize and stimulate the healing of a variety of skin and tissue conditions. The transdermal delivery system allows for the targeted delivery of active ingredients, vitamins and herbs through the skin to the underlying tissue.

The company has utilized its transdermal delivery system to develop a safe and effective female sexual enhancement product. The company's goal is to develop a portfolio of topical pharmaceutical and cosmeceutical products targeting various skin and tissue conditions including: scars and stretch marks, cellulite and varicose veins.

RECENT ARTICLES AND PUBLICATIONS

Burzynski: Cancer Is Serious Business – <http://vimeo.com/24821365>

Cancer Breakthrough: 50-60% Success Rate, Cures the Incurable - <http://articles.mercola.com/sites/articles/archive/2011/05/21/drs-stanislaw-and-gregory-burzynski-on-cancer.aspx>

Dr. Oz speaks to Dr. Burzynski & Eric Merola - <http://www.youtube.com/watch?NR=1&v=HVejUrKnh6E>

Suzanne Somers Visits the Burzynski - <http://www.youtube.com/watch?v=K1S7XDHC2VA&NR=1>

INDUSTRY OVERVIEW

The Medical industry and treatment is a very generic term with numerous players that can be included. For this research report, the main focus is Cancer Research, Treatment, and Cure which is what Burzynski Research Institute continues to focus on.

The cancer industry is quite large which generates in excess of approximately \$200 billion per year worldwide.


The largest “corporation” that exists to today is, of course, the American Cancer Society (ACS) which they receive contributions and donations from over 300 industries & corporations - with an annual budget of \$800 Million.

To review a detail report on Cancer facts and figures by The American Cancer Society, follow their link at

<http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/docume nt/acspc-029771.pdf>

Some of the more notable players in the Cure and Treatment of Cancer patients:

- IDEC Pharmaceuticals, Rituxan® [rituximab], - After reporting its first year of profitability in 1998, shares of IDEC Pharmaceuticals traded at a new all-time high of \$140 with a market capitalization above \$3.3 billion
- GlaxoSmithKline plc /Genmab A/S, Arzerra® [ofatumumab]
- Roche Group, Avastin® [bevacizumab], Rituxan®, and Herceptin® [trastuzumab] – collectively represented nearly US\$17 billion in revenue for 2009
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Biovest International, Inc



COMPANY INFORMATION AND ANALYSIS

The Company & Technology

Dr. Stanislaw R. Burzynski commenced his cancer research in 1967 focusing on the isolation of various biochemicals produced by the human body as part of the body's possible defense against cancer. In the course of his research, Dr. Burzynski identified certain peptides, amino acid derivatives and organic acids in these biochemicals which appear to inhibit the growth of cancer cells. Dr. Burzynski named these derivatives antineoplastons.

Antineoplastons are found in the body fluids of humans and in foods, and initially were isolated by Dr. Burzynski from normal human blood and urine. Dr. Burzynski believes these substances counteract the development of cancerous growth through a biochemical process which does not inhibit the growth of normal tissues. All of the Phase II clinical trials currently sponsored by BRI involve the use of two formulations of synthetic ANP known as A10 and AS2-1 injections. BRI is also conducting laboratory research involving new generations of Antineoplastons A10 and AS2-1.

Antineoplaston (ANP) is a name coined by Stanislaw Burzynski for a group of peptides, derivatives, and mixtures that he uses as an alternative cancer treatment.

These compounds are seeking FDA approval and are currently sold and administered by Burzynski as part of clinical trials that he runs at his own establishments, the Burzynski Clinic and the Burzynski Research Institute in Houston, Texas.

BRI currently intends to focus its efforts on the clinical development of its Antineoplastons A10 and AS2-1 for the treatment of brainstem glioma, which is the indication for which it received "orphan drug designation" from the FDA. BRI anticipates commencing Phase III trials during 2011, which will involve the treatment of newly diagnosed children with inoperable brainstem glioma

BRI began Phase II clinical trials in 1994 with four studies. Currently, BRI sponsors 5 ongoing Phase II clinical trials, which are conducted pursuant to investigational new drug applications (INDs) filed with the FDA and approved by an Institutional Review Board (IRB) designed according to federal regulations. All of the trials involve the use of intravenous formulations of ANP. Dr. Burzynski acts as principal investigator for all clinical trials. Prior to approving a New Drug Application (NDA), the FDA requires that drug safety and efficacy be demonstrated in well-controlled clinical trials. The ultimate

goal of all treatment for cancer is patient survival. However, the FDA has determined that requiring exhaustive data showing improved patient survival may unnecessarily delay the approval of new cancer drugs. For that reason, the FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug has an effect on a surrogate endpoint (milestone) that is reasonably likely to predict clinical benefit. Each of BRI's Phase II trials describes such milestones which are used to determine success or failure of the treatment employed.

In most of the trials, the milestones are radiographic evidence of tumor shrinkage by x-ray, computer aided tomography (CT) or magnetic resonance imaging (MRI). Where tumor size is used as the milestone, each clinical trial protocol describes a complete response (CR) as the complete disappearance of all tumors with no reoccurrence of tumor for at least four weeks. A partial response (PR) is described as at least a 50% reduction in total tumor size, with such reduction lasting at least four weeks. Stable disease (SD) is described as less than 50% reduction in tumor size, but no more than 50% increase in size of the tumor mass, lasting for at least 12 weeks. In 2008, twelve of the prospective clinical trials reached a milestone. Unfortunately, there can be no assurance that the results of any of these trials can be repeated, or that the other clinical trials will result in the same or similar responses.

Notwithstanding the response results of the trials that have reached a milestone, BRI management believes it is likely that the FDA may require additional clinical trials based upon such protocols to be conducted by an institution not affiliated with BRI

PRICE PERFORMANCE AND CHART HISTORY**BZYR Fri. Nov 4th, 2011· Close: \$0.30****Barchart Opinion: Strong Buy**

Barchart Opinion
» View Opinion
Strong Buy
Buy
Hold
Sell
Strong Sell

Support & Resistance	
» Get Cheat Sheet	
2nd Resistance Point	0.3400
1st Resistance Point	0.3200
Last Price	0.3000
1st Support Level	0.2600
2nd Support Level	0.2200

Burzynski Research (BZYR)

0.3000 ↑ +0.0400 (+15.38%) HELP			
Stock Price Quote as of Friday, Nov 4th, 2011 (OTC-BB)			
High	0.3000	Low	0.2400
52Wk High	0.3000	52Wk Low	0.0700
Open	0.2800	Prev Close	0.2600
Volume	233233	Avg Volume	26180
EPS	N/A	Div & Yield	N/A
P/E Ratio	N/A	Market Cap	N/A
Weighted Alpha	-7.59	Standard Dev	+1.06

Chart Snapshot [» Customize Chart](#)**Syndicate Related Article****(Xtremepicks.com Friday Nov 4th, 2011)****BZYR – Perfect set-up for MEGA Gains next week.**

Congrats to our members of a huge winning week and those who held on to our long term picks, DROP (DEGH), and BZYR which made solid gains this week.

Members who held BZYR since our initial alert at \$0.13 more than doubled their value this week with today's \$0.30 close - **closing at the all-time high**. Major accumulation this week in anticipation of monster news expected is setting up for a major week ahead. FDA approval may be just a stone throw away.

DEGH is already our huge 50,000% gainer from our initial alert at \$0.0014 which hit our \$0.75 target level earlier this year. **Members who jump on our re-alert at \$0.15 a few weeks back, is sitting nicely on 150% gains.**

The key to these plays and all our long term picks is patience, and scooping up cheap shares on any minor pull backs as mega rewards will follow.

**BURZYNSKI RESEARCH INSTITUTE, INC.**

DEGH, and BZYR is locked and loaded for much more gains next week as we look towards updates that is set to skyrocket prices.

If there's ever a hint that something big is ready to be unleashed it is how BZYR traded this week as smart accumulation pushed prices to its all-time high.

Watch the MUST SEE BZYR's Video that shows **its** amazing Cancer treatment – you will be blown away.

You can view the video at <http://vimeo.com/24821365>

We anticipate the company is near releasing a big update on their cancer treatment and if the company announces FDA approval, BZYR can move like wildfire. All bets are off where this can head to.

FDA approval of national distribution and administration of their treatment can be worth billions for BZYR!

BZYR closed at \$0.30 and at an all-time high. Volumes have been much higher than normal with all signals pointing to a breakout. With mega news expected, BZYR can really heat up.

How much would a Cure for Cancer be worth? Concentrate that into a company, **valuations can go off the charts. BZYR** already presented data to back up their claims **that their treatment in cancer patients resulted in overwhelming success.**

Dr. Burzynski of **BZYR** stresses that he has the solution to treat and cure Cancer patients and have the research and results to back up his claims. **Dr. Burzynski also invested millions of his own funds in the company, definitely showing commitment to his “Cancer Cure”.**

With more clinical trials and seeking FDA approval of national distribution and administration of their treatment, **BZYR** is presenting an amazing opportunity with huge upside potential.

Burzynski Research Institute (BRI), a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and developmental efforts are focused on cancer treatment with two pipeline drugs—antineoplastons (ANP) in one Phase III clinical trial and 5 Phase II clinical trials. Two additional Phase III trials are being discussed with the FDA. The ultimate goal of the BRI is to discover, develop, and obtain the FDA's marketing approval of ANP for the treatment of currently incurable types of cancer with emphasis on malignant brain tumors in adults and children.

DISCLOSURES

Direct Global Media (DGM) and Direct Global Media Research (DGMR) Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of DGM. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by DGMR for non-investment banking services. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.

DGM R or DGM do not make a market in any security nor do they act as dealers in securities. DGMR has never received compensation for investment banking services on the small-cap universe. DGMR does not expect received compensation for investment banking services on the small-cap universe. DGMR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by DGMR. Non-investment banking services include investor relations, and advertising services.

Additional information is available upon request. DGMR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by DGMR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. DGMR uses the following rating system for the securities it covers. Buy/Strong Buy: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Strong Sell: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

Data is as of midnight on the business day immediately prior to this publication